Health Professional Radio - Podcast

Sebastian Seiguer, CEO of Scene Health, and Dr. Kevin Hallgren of the University of Washington School of Medicine discuss the benefits of video observation of methadone dosing for patient safety, policy, and the behavioral health backlog. Dr. Hallgren is the lead author of a study, published in the Journal of Substance Abuse Treatment, which evaluated the feasibility, acceptability, and engagement of smartphone-based video observation of methadone take-home dosing during the COVID-19 pandemic. The CEO of Scene Health and a doctor from the University of Washington School of Medicine talk about the advantages of video observation of methadone dosing for patient safety, policy, and the behavioral health backlog. The doctor led a study, published in the Journal of Substance Abuse Treatment, which looked at the feasibility, acceptability, and engagement of using smartphone-based video observation of methadone take-home dosing during the COVID-19 pandemic. The CEO of Scene Health and a doctor discuss the benefits of video observation of methadone dosing for patient safety, policy, and the behavioral health backlog. The doctor led a study that looked at the feasibility, acceptability, and engagement of using smartphone-based video observation of methadone take-home dosing during the COVID-19 pandemic. #SceneHealth Sebastian is the CEO and co-founder of Scene, a medication engagement company that improves medication adherence through personalized support using video technology, clinical coaching, and validated interventions. Scene was founded in 2014 by Sebastian and Dr. Bob Bollinger, along with other medication adherence experts, at Johns Hopkins University to serve public health departments, health plans including Medicaid and Medicare, and health systems. Scene is now the standard of care for infectious disease adherence monitoring and is growing rapidly. Prior to starting Scene, Sebastian worked as an attorney in London and founded a company in Munich. He holds a law degree from Columbia Law School and an MBA in Health Care from Johns Hopkins University.

Neuromyelitis Optica Spectrum Disorder (NMOSD) by Vertical Internet Media

The High Rate of Addiction Among Native Americans by Vertical Internet Media

CDC Reviews Flu Vaccines for 65+ by Vertical Internet Media

agilon health Partners with MaineHealth by Vertical Internet Media

Pediatric Heart Health Risks and Benefits From COVID-19 Vaccinations by Vertical Internet Media

Returning guest, Dr. Bruce Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai discusses new data presented at the 16th Congress of European Crohn's and Colitis Organisation (ECCO) from a trial evaluating biologic induction and maintenance therapy for moderately to severely active ulcerative colitis. Bruce E. Sands, M.D., M.S., Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai Hospital and the Dr. Burrill B. Crohn Professor of Medicine (Gastroenterology), at the Icahn Institute for Medicine at Mount Sinai is the study spokesperson for the three-year data from the long-term extension (LTE) of UNIFI, a Phase 3 protocol designed to evaluate the safety and efficacy of STELARA induction and maintenance dosing for the treatment of moderately to severely active ulcerative colitis in adults who demonstrated an inadequate response to or were unable to tolerate conventional (e.g., corticosteroids, immunomodulators) or biologic (e.g., one or more TNF blockers or vedolizumab) therapies. Dr. Sands' clinical research includes treating inflammatory bowel disease and clinical investigations of new therapeutics. He serves as a reviewer for the New England Journal of Medicine and is a fellow of the American College of Gastroenterology and the American Gastroenterological Association.